Trial Profile
A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1.0% and 2.5% Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2016
Price :
$35
*
At a glance
- Drugs Urocanic acid (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Herantis Pharma
- 04 Jan 2016 Primary endpoint has not been met. (Symptom Score), as reported by Herantis media release.
- 04 Jan 2016 Primary endpoint has not been met. (Corneal Fluorescein Staining), as reported by Herantis media release.
- 08 Sep 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov.